-
CAS NUMBER
81131-70-6 -
FORMULATION
A - ORAL SOLID ORDINARY -
THERAPEUTIC CATEGORY
C-CARDIOVASCULAR SYSTEM -
STATUS
Commercial -
REGULATION
US DMF , CEP , EU DMF , Japan DMF , Korea DMF , Other
-
About the API
-
Trade Name(s): Pravachol, Selektine, Lipostat
Systematic Name: Sodium (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[[(2S)-methylbutanoyl]oxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoate
Molecular Formula: C23H35NaO7
Molecular Weight: 446.5 g/mol (anhydrous)
Physical Properties: White/off-white crystalline powder
-
-
API Expertise
-
The API expertise for producing Pravastatin sodium is Fermentation
For more information about Fermentation please click here.
-
-
General
-
Pravastatin belongs to the family of lipid-lowering compounds known as 'statins'. Broadly, statins work to reduce the level of low-density lipoprotein (LDL) cholesterol in the blood by inhibiting the liver enzyme responsible for its production.
High blood cholesterol levels are associated with cardiovascular diseases such as dyslipidemia (abnormal blood lipid level) and atherosclerosis (narrowing of the artery walls by accumulation of fatty deposits, or 'plaques').
Statins are thus primarily indicated for the prevention and treatment of such diseases. Pravastatin is typically indicated as an adjunct to a cholesterol-reduced diet.
Originally disclosed and claimed in U.S Pat. No. 4.410.629, pravastatin is marketed by Sankyo Pharma Inc. (Japan) and Bristol-Myers-Squibb (outside Japan) under the trade name Pravachol.
As of April 2006, Pravas-tatin Sodium is available in several generic formulations. Pravastatin is presently manufactured by large-scale fermentation, a well-established industrial method using microorganisms to convert raw materials to valuable commercial product through chemical transformations. Through careful strain selection and continuous strain improvement, the process has been streamlined for maximum productivity and yield.
-
-
Mechanism of Action
-
There are two pathways by which pravastatin is thought to lower lipid levels. First, the drug is a reversible inhibitor of the liver enzyme 3-hydroxy-3-methylglutaryl-Co-A reductase (HMG-CoA); this action causes the disruption an early rate-limiting step of the cholesterol biosynthetic pathway in which HMG-CoA is converted to mevalonate.
The overall result is an increase the number of cellular LDL receptors, which help to remove excess LDL from the bloodstream. Second, pravastatin is thought to inhibit very-low-density lipoprotein (VLDL) synthesis, the precursor to LDL.
-
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact TAPI Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes
-
Visitors also viewed
-
111470-99-6
Amlodipine besylate
Innovators / Marketer
PfizerFORMULATION
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGTHERAPEUTIC CATEGORY
C-CARDIOVASCULAR SYSTEMAvailable DMF/CEP
- US DMF
- CEP
- EU DMF
-
29122-68-7
Atenolol
Innovators / Marketer
Astra ZenecaFORMULATION
A - ORAL SOLID ORDINARYTHERAPEUTIC CATEGORY
C-CARDIOVASCULAR SYSTEMAvailable DMF/CEP
- US DMF
- CEP
- EU DMF
- Japan DMF
-
134523-03-08
Atorvastatin calcium
Innovators / Marketer
PfizerFORMULATION
A - ORAL SOLID ORDINARYTHERAPEUTIC CATEGORY
C-CARDIOVASCULAR SYSTEMAvailable DMF/CEP
- US DMF
- CEP
- EU DMF
- Korea DMF
- Canada DMF
- Brazil DMF
- Other
-
- Load More
-